$85.45
-0.19-0.22%
At close: -
$86.00
0.550.64%
After Hours: 4:48 PM EDT
Comments
Loading...
Intra-Cellular Therapies (NASDAQ:ITCI) Stock, Earnings Estimates, EPS, And Revenue
Intra-Cellular Therapies reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Feb 20
EPS Estimate
$-0.150
Quarterly Revenue Estimate
$188.6M
Annual Revenue
(as of Sep 30)
(as of Sep 30)
$612.8M
Analyze the earnings history of Intra-Cellular Therapies using advanced sorting and filters.
Data brought to you by Benzinga APIs
Intra-Cellular Therapies (ITCI) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-10-30 | $-0.25 | $-0.20 | -25.0 % |
| Jun 2024 | 2024-08-07 | $-0.16 | $-0.19 | 15.8 % |
| Mar 2024 | 2024-05-07 | $-0.16 | $-0.33 | 51.5 % |
| Dec 2023 | 2024-02-22 | $-0.30 | $-0.43 | 30.2 % |
Intra-Cellular Therapies (ITCI) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-10-30 | $175.38M | $172.35M | 1.76 % |
| Jun 2024 | 2024-08-07 | $161.39M | $157.88M | 2.22 % |
| Mar 2024 | 2024-05-07 | $144.87M | $140.91M | 2.81 % |
| Dec 2023 | 2024-02-22 | $132.10M | $136.79M | -3.43 % |
FAQ
When is Intra-Cellular Therapies (NASDAQ:ITCI) reporting earnings?
Intra-Cellular Therapies (ITCI) is scheduled to report earnings on February 20, 2025. The last reported earnings were for reported on October 30, 2024 for Q3.
What were the latest earnings per share (EPS) for Intra-Cellular Therapies (NASDAQ:ITCI)?
The Actual EPS was $-0.25, which missed the estimate of $-0.20.
What were Intra-Cellular Therapies’s (NASDAQ:ITCI) revenues?
The Actual Revenue was $175.4M, which beat the estimate of $172.3M.
Browse earnings estimates, EPS, and revenue on all stocks.